New GABA-targeting therapies for the treatment of seizures and epilepsy: II. Treatments in clinical development. CNS Drugs 37, 781–795 (2023). Article CAS PubMed PubMed Central Google Scholar Cerne, R. et al. GABAkines — advances in the discovery, development, and commercialization of ...
New epilepsy treatmentsThe article offers information on the suggested epilepsy treatments from the National Institute for Health and Clinical Excellence (NICE) of Great Britain which include buccal midazolam, rectal diazepam, and intravenous lorazepam.Pulse...
Hope for new treatments for acute repetitive seizures. Editorial For reprint orders, please contact reprints@future-science.com Therapeutic Delivery The potential use of trigeminal nerve stimulation in the trea... David,Spencer - 《Epilepsy Currents》 被引量: 6发表: 2014年 In vitro and in vivo ...
helpful resources and encourage them to seek sustained treatment. Developing targeted CUD treatments for pregnant populations is crucial due to increasing CUD rates,
All other treatments will be allowed. Provisions for post-trial care Any patients who suffer harm from trial participation will be covered by the Japanese public healthcare system. Clinical assessments On enrollment in this trial, clinical research physicians will obtain information from the patients ...
conference, we will be continuing with debates as well as adhering to the format of the previous conferences which are designed to provide an in-depth progress report on new antiepileptic drugs in various stages of development, as well as to present new findings on second-generation treatments. ...
Dr. Lina Rodriguez Rosario, a neurologist at Health First’s Holmes Regional Medical Center, has been using VNS with epilepsy patients for five years and believes its expanded use to help stroke recovery is an important development. “The main difference for the new application is in the device...
Crick, said, "At the moment, there's a clear need for drugs that specifically target the biological nature of CDD. We've made a molecular link between CDKL5 and Cav2.3, mutations which produce similar disorders. Inhibiting Cav2.3 could be a route for trials of future targeted treatments."...
Therefore, in our study, affected individuals should be given 1 mg or 5 mg of vitamin B12 intramuscularly every day for five days, followed by an assessment of the production of related metabolites to judge whether the treatments were effective. For example, an improvement in clinical symptoms ...
“We hope in this way to develop long term treatments that induce lung tissue repair in the patients.” In the future, the research team believes their findings can contribute to drug development and mechanistic studies in patient derived lung tissue. Eventually, they hope their discovery will ...